Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11246349 | 0.93 | CA1 (0.69) | CA1CA2ALDH1A1POLBHPGD | |
| SCHEMBL5211384 | 0.92 | ALDH1A1 (0.65) | CA1CA2ALDH1A1POLBHPGD | |
| SCHEMBL1446643 | 0.92 | CA1 (0.70) | CA1CA2ALDH1A1POLBHPGD | |
| SCHEMBL11253071 | 0.91 | AGER (0.64) | CA1CA2ALDH1A1POLBHPGD | |
| SCHEMBL16550429 | 0.91 | FFAR1 (0.67) | CA1CA2ALDH1A1POLBHPGD | |
| SCHEMBL2647499 | 0.91 | ALDH1A1 (0.72) | CA1CA2ALDH1A1POLBHPGD | |
| SCHEMBL4562716 | 0.91 | TPMT (0.59) | CA1CA2ALDH1A1POLBHPGD | |
| SCHEMBL11414793 | 0.91 | FFAR1 (0.67) | CA1CA2ALDH1A1POLBHPGD | |
| SCHEMBL11413950 | 0.91 | ALDH1A1 (0.69) | CA1CA2ALDH1A1POLBHPGD | |
| SCHEMBL11246224 | 0.91 | ALDH1A1 (0.72) | CA1CA2ALDH1A1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276036-A1 | Non-Glycosidic and Non-Peptidic Select Inhibitors, and the Use Thereof | JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2007-11-29 | — | — | US | claimed |
| US-7485742-B2 | Non-glycosidic and non-peptidic inhibitors of selectin, and the use thereof | Johannes Gutenberg-Universität Mainz (DE) | 2009-02-03 | — | — | US | disclosed |
| US-20070276036-A1 | Non-Glycosidic and Non-Peptidic Select Inhibitors, and the Use Thereof | JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276036-A1 | Non-Glycosidic and Non-Peptidic Select Inhibitors, and the Use Thereof | VCAM1, ICAM1, SELPLG | CA1 1636/4885CA2 3425/4885ALDH1A1 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.